How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats

Journal of Orthopaedic Research

Volumn 24, Issue 5, 2006, Pages 1128-1135

  Shen, Jian ^a   Ma, Jianjun ^a   Lee, Cassandra ^a   Smith, Beth P ^a   Smith, Thomas L ^a   Tan, Kim H ^a   Koman, L Andrew ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Botulinum toxin; Gene; Microarray; Neuromuscular junction; Rats

Indexed keywords

BOTULINUM TOXIN A; MESSENGER RNA; SODIUM CHLORIDE; SOMATOMEDIN C; CHOLINERGIC RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MUSK PROTEIN, RAT; MYOG PROTEIN, RAT; MYOGENIN; NICOTINIC RECEPTOR; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOLOGY; DOWN REGULATION; DRUG DOSE REGIMEN; GASTROCNEMIUS MUSCLE; GENE EXPRESSION PROFILING; GENE TECHNOLOGY; GENETIC IDENTIFICATION; HINDLIMB; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE REGENERATION; NEUROMUSCULAR SYNAPSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARESIS; PRIORITY JOURNAL; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; UNINDEXED SEQUENCE; UPREGULATION; ANIMAL; ATROPHY; DNA MICROARRAY; DRUG EFFECT; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; NERVE REGENERATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SKELETAL MUSCLE; SPRAGUE DAWLEY RAT;

ANIMALS; ATROPHY; BOTULINUM TOXIN TYPE A; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GENE EXPRESSION PROFILING; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SKELETAL; MYOGENIN; NERVE REGENERATION; NEUROMUSCULAR JUNCTION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARESIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RECEPTORS, NICOTINIC;

EID: 33744484015     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20131     Document Type: Article

References (24)

1. Koman LA, Brashear A, Rosenfeld S, et al. 2001. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108:1062-1071.
2. Tilton AH. 2003. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol 18(Suppl 1):S50-S66.
3. Aoki KR, Guyer B. 2001. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 8(Suppl 5):21-29.
4. Cosgrove AP, Graham HK. 1994. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 36:379-385.
5. Ma J, Elsaidi GA, Smith TL, et al. 2004. Time course of recovery of juvenile skeletal muscle after botulinum toxin A injection: an animal model study. Am J Phys Med Rehabil 83:774-780.
6. Alderson K, Holds JB, Anderson RL. 1991. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 41:1800-1805.
7. Ma J, Shen J, Lee CA, et al. 2005. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: a study in rats. J Orthop Res 23:302-309.
8. Santos AF, Caroni P. 2003. Assembly, plasticity and selective vulnerability to disease of mouse neuromuscular junctions. J Neurocytol 32:849-862.
9. Raftery MA, Hunkapiller MW, Strader CD, et al. 1980. Acetylcholine receptor: complex of homologous subunits. Science 208:1454-1456.
10. Buonanno A, Merlie JP. 1986. Transcriptional regulation of nicotinic acetylcholine receptor genes during muscle development. J Biol Chem 261:11452-11455.
11. DeChiara TM, Bowen DC, Valenzuela DM, et al. 1996. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85:501-512.
12. Herbst R, Avetisova E, Burden SJ. 2002. Restoration of synapse formation in Musk mutant mice expressing a Musk/Trk chimeric receptor. Development 129:5449-5460.
13. Charbonnier F, Della GB, Armand AS, et al. 2003. Specific activation of the acetylcholine receptor subunit genes by MyoD family proteins. J Biol Chem 278:33169-33174.
14. Weintraub H, Davis R, Tapscott S, et al. 1991. The myoD gene family: nodal point during specification of the muscle cell lineage. Science 251:761-766.
15. Shen J, Ma J, Elsaidi GA, et al. 2005. Gene expression of myogenic regulatory factors following intramuscular injection of botulinum A toxin in juvenile rats. Neurosci Lett 381:207-210.
16. Gartel AL, Tyner AL. 1999. Transcriptional regulation of the p21((WAF1/ CIP1)) gene. Exp Cell Res 246:280-289.
17. Walsh K. 1997. Coordinate regulation of cell cycle and apoptosis during myogenesis. Prog Cell Cycle Res 3:53-58.
18. Musaro A, McCullagh K, Paul A, et al. 2001. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195-200.
19. Frost RA, Nystrom GJ, Lang CH. 2002. Regulation of IGF-I mRNA and signal transducers and activators of transcription-3 and -5 (Stat-3 and -5) by GH in C2C12 myoblasts. Endocrinology 143:492-503.
20. Louis M, Van BR, Dehoux M, et al. 2004. Creatine increases IGF-I and myogenic regulatory factor mRNA in C(2)C(12) cells. FEBS Lett 557:243-247.
21. Li L, Oppenheim RW, Lei M, et al. 1994. Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. J Neurobiol 25:759-766.
22. Flint PW, Shiotani A, O'Malley BW Jr. 1999. IGF-1 gene transfer into denervated rat laryngeal muscle. Arch Otolaryngol Head Neck Surg 125:274-279.
23. Piehl F, Ji RR, Cullheim S, et al. 1995. Fibroblast growth factors regulate calcitonin gene-related peptide mRNA expression in rat motoneurons after lesion and in culture. Eur J Neurosci 7:1739-1750.
24. Ewton DZ, Coolican SA, Mohan S, et al. 1998. Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5: a dual role for IGFBP-5. J Cell Physiol 177: 47 -57.